A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

Clinical trial NCT07080021 · RECRUITING

Trial details

NCT number: NCT07080021
Sponsor: Ruijin Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

Borderline Resectable Pancreatic Adenocarcinoma Resectable Pancreatic Adenocarcinoma

Start date: 2025-05-20
Primary completion: 2026-05-20
Enrollment: 119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.